About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

On Thursday, the FDA approved Bristol Myers Squibb & Co’s BMY Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.Bristol-Myers added the treatment via Karuna Therapeutics deal for $330 per share in cash for a total equity value of $14 billion.Cobenfy represents the first new class of medicine in several decades and introduces a fundamentally new approach to treating schizophrenia by selectively targeting M1 and M4 receptors in the brain without blocking D2 rece ...

Taking into account the most recent developments, particularly the KarXT ( Cobenfy ) FDA approval , which is poised to be a game changer in the treatment of Schizophrenia, together with the significant advances in the oncology portfolioOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineerings, and +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs including orthopaedics and rare diseases. As an investor, I have been utilising m ...

29 August 2024, Bavaria, Munich: The logo of the pharmaceutical company Bristol-Myers Squibb, (BMS) ... [+] is seen on the facade of the company's Munich headquarters on August 29, 2024 in Munich (Bavaria). The global biopharmaceutical company is engaged in the research, development and readiness of innovative medicines for patients with serious diseases. Photo: Matthias Balk/dpa (Photo by Matthias Balk/picture alliance via Getty Images)dpa/picture alliance via Getty ImagesBristol Myers Squibb stock (NYSE: ...

The Food and Drug Administration on Thursday approved Bristol Myers Squibb's highly anticipated schizophrenia drug Cobenfy, the first novel type of treatment for the debilitating, chronic mental disorder in more than seven decades. Schizophrenia affects how a person thinks, feels and behaves, and can cause paranoia, delusions, hallucinations, and changes in emotions, movements and behavior. Those symptoms can disrupt a patient's everyday life, making it difficult to go to school or work, socialize and compl ...

These two stocks have had their issues in recent years, but both look like reliable long-term bets.Investing in stocks is one of the most accessible and reliable ways to generate wealth over long periods for at least two reasons. First, equities are pretty much guaranteed to be in a general northbound direction over several decades. Second, it is possible to start getting in on the act, even with a relatively modest sum of money.For those with $200 to spare that isn't being saved for emergencies, let's cons ...

Bristol Myers Squibb Company (BMY) is experiencing a good run of late after touching a 52-week low of $39.35 on July 5. This short rally has given anxious investors a ray of hope. The biotech giant has been facing a few challenges for quite some time now.Shares of BMY have risen 16.2% in the past three months compared with the industry’s growth of 3.8%. The stock has also outperformed the sector and the S&P 500 during this time frame.Much of this outperformance can be attributed to the company’s better-than ...

Forbes Community GuidelinesOur community is about connecting people through open and thoughtful conversations. We want our readers to share their views and exchange ideas and facts in a safe space.In order to do so, please follow the posting rules in our site's Terms of Service.  We've summarized some of those key rules below. Simply put, keep it civil.Your post will be rejected if we notice that it seems to contain:False or intentionally out-of-context or misleading informationSpamInsults, profanity, incoh ...

These dividend payers could more than double their payouts in the decade ahead.Despite a lousy market performance during the week ended Sept. 6, the past 20 months have been an extraordinary time for most investors. The benchmark S&P 500 index has soared 40.9% since the end of 2022.A rough start to the month of September was a harsh reminder that markets rarely rise steadily. After over a year and a half of strong gains, another bear market could be around the corner.In precarious times like these, investin ...

JHVEPhoto/iStock Editorial via Getty Images Bristol-Myers Squibb Company (NYSE:BMY) produced its best bottom-line beat in more than five years back in July. Shares rose significantly after reporting, helping the broader Health Care Select Sector SPDR ETF (XLV) sector begin a period of outperformance against the S&P 500 ETF (SPY). It’s almost always a favorable setup when we see a gangbuster company earnings update, just as sector relative strength turns for the better. Not surprisingly, BMY shares are ...